Perspective Therapeutics Target Price

Explore Perspective Therapeutics's target price with historical charts and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.26

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-03-17	Truist FinancialGreg Renza	$12	268.1% upside
2026-02-19	Piper SandlerBiren Amin	$16	390.8% upside
2026-01-30	H.C. Wainwright	$12	268.1% upside
2025-11-21	UBSDavid Lai	$7	114.7% upside
2025-10-10	BTIGJeet Mukherjee	$14	329.4% upside
2024-10-24	UBSDavid Dai	$20	513.5% upside
2024-10-14	OppenheimerJeff Jones	$22	574.8% upside
2024-09-25	Truist FinancialNicole Germino	$21	544.2% upside
2024-07-25	Bank of America SecuritiesAlec Stranahan	$24	636.2% upside
2024-06-18	OppenheimerJeff Jones	$19	482.8% upside
2024-06-14	RBC CapitalGregory Renza	$3	8% downside
2024-05-15	OppenheimerJeff Jones	$2	38.7% downside

Perspective Therapeutics (CATX) FAQ

Stockcircle tracks target price for Perspective Therapeutics (CATX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Perspective Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main CATX overview so you can move from this figure to the surrounding analysis quickly.